QTNT - Quotient Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.69
+0.11 (+1.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.58
Open7.66
Bid4.60 x 800
Ask8.44 x 2200
Day's Range7.53 - 7.78
52 Week Range2.78 - 9.02
Volume340,788
Avg. Volume590,790
Market Cap351.864M
Beta0.09
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Quotient Limited Announces Details of Investor Day

    Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’s headquarters to provide an update on the progress towards the commercialization of MosaiQ.  Information presented included a demonstration of the features of the MosaiQ instrument designed to bring automated high throughput microarray based diagnostic testing to transfusion diagnostics and beyond. Franz Walt, Quotient’s CEO, presented the Quotient strategy for MosaiQ and the unique opportunity in the large transfusion diagnostics market. In addition, a voice of customer video described that market’s urgent need for innovation.  Jeremy Stackawitz, the Company’s President of Commercial, explained how MosaiQ’s unique product design is expected to meet the stated need of customers in an affordable automated format designed to deliver value through a reduction in the total cost of ownership when compared to currently available solutions.

  • GlobeNewswire16 days ago

    Quotient Limited Announces Completion of Senior Secured Notes Offering

    Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29, 2018, the Company, completed the second and final closing (the “Second Closing”) of its offering of the Notes. Upon the Second Closing, the Company issued an additional $36.0 million aggregate principal amount of the Notes (the “Additional Notes”).

  • ACCESSWIRE20 days ago

    Complimentary Technical Snapshots on Valeant Pharmaceuticals International and Three More Healthcare Stocks

    Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...

  • Analysts Expect Breakeven For Quotient Limited (NASDAQ:QTNT)
    Simply Wall St.22 days ago

    Analysts Expect Breakeven For Quotient Limited (NASDAQ:QTNT)

    Quotient Limited’s (NASDAQ:QTNT): Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The US$402.65m market-cap companyRead More...

  • GlobeNewswirelast month

    Quotient Limited to Host Investor Day on July 16, 2018

    JERSEY, Channel Islands, June 18, 2018-- Quotient Limited, a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am– 1:00pm ET, in ...

  • GlobeNewswirelast month

    Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial

    Quotient Limited (QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceed the targeted criteria for submission for CE marking. Under the terms of the indenture governing its 12% Senior Secured Notes due 2023, Quotient now plans to issue an additional $36 million of notes with funding to occur within 10 business days of the date of this press release. “It gives me great pleasure to report positive field trial results for our initial blood grouping microarray,” said Franz Walt, Chief Executive Officer of Quotient.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of QTNT earnings conference call or presentation 29-May-18 12:00pm GMT

    Q4 2018 Quotient Ltd Earnings Call

  • Associated Press2 months ago

    Quotient: Fiscal 4Q Earnings Snapshot

    On a per-share basis, the Eysins, Jersey-based company said it had a loss of 44 cents. The blood test developer posted revenue of $6.1 million in the period. For the year, the company reported that its ...

  • GlobeNewswire2 months ago

    Quotient Limited Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ™ European Field Trials

    MosaiQ European field trial which commenced on May 17, 2018 is ongoing Franz Walt is appointed as Chief Executive Officer Fourth quarter product revenues of $6.1 million, up 29.6% JERSEY, Channel Islands, ...

  • GlobeNewswire2 months ago

    Quotient Limited appoints Franz Walt as Chief Executive Officer

    Quotient Limited (QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers, Laboratory Diagnostics, is a member of Quotient's Board of Directors, and had been appointed as the interim Chief Executive Officer recently in March.

  • Why Quotient Ltd. Is Soaring Today
    Motley Fool2 months ago

    Why Quotient Ltd. Is Soaring Today

    Traders cheer after the company shares some good news with investors. Here's what shareholders need to know.

  • GlobeNewswire2 months ago

    Quotient Limited Reports Commencement of EU Blood Grouping Field Trial

    Quotient Limited (QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European field trials. “I am very pleased to announce the start of our European field trials for IH I. This is the next important step in our rigourous development process, that included the V&V performance data which we have previously shared.

  • GlobeNewswire2 months ago

    Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call

    JERSEY, Channel Islands, May 15, 2018-- Quotient Limited, a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018, ...

  • Quotient Limited (NASDAQ:QTNT): Does The -11.14% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.4 months ago

    Quotient Limited (NASDAQ:QTNT): Does The -11.14% Earnings Drop Reflect A Longer Term Trend?

    Understanding how Quotient Limited (NASDAQ:QTNT) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense check toRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of QTNT earnings conference call or presentation 6-Feb-18 1:30pm GMT

    Q3 2018 Quotient Ltd Earnings Call

  • Associated Press5 months ago

    Quotient reports 3Q loss

    The Eysins, Jersey-based company said it had a loss of 47 cents per share. The blood test developer posted revenue of $5.9 million in the period. Quotient expects full-year revenue in the range of $24.1 ...